tiprankstipranks
Advertisement
Advertisement

CRVO Stock Latest News

CervoMed announces $10M registered direct offering priced at-the-market
The FlyCervoMed announces $10M registered direct offering priced at-the-market
2d ago
CRVO
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
PremiumCompany Announcements
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
2d ago
8K
CRVO
CervoMed receives notice of allowance from USPTO on neflamapimod
PremiumThe Fly
CervoMed receives notice of allowance from USPTO on neflamapimod
3d ago
CRVO
CervoMed Posts Updated Investor Presentation and Business Overview
PremiumCompany Announcements
CervoMed Posts Updated Investor Presentation and Business Overview
5d ago
8K
CRVO
CervoMed Announces Private Placement to Advance Neurology Pipeline
PremiumCompany Announcements
CervoMed Announces Private Placement to Advance Neurology Pipeline
10d ago
8K
CRVO
CervoMed announces $10.5M private placement
PremiumThe FlyCervoMed announces $10.5M private placement
10d ago
CRVO
CervoMed announces $10.5M private placement
Premium
The Fly
CervoMed announces $10.5M private placement
10d ago
CRVO
CervoMed Shareholders Back Board, Pay and Incentive Plan
Premium
Company Announcements
CervoMed Shareholders Back Board, Pay and Incentive Plan
12d ago
8K
CRVO
CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
PremiumRatings
CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
1M ago
CRVO
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
PremiumRatings
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
1M ago
CRVO
CervoMed Highlights Q1 Results and Neflamapimod Progress
PremiumCompany Announcements
CervoMed Highlights Q1 Results and Neflamapimod Progress
1M ago
8K
CRVO
CervoMed price target lowered to $9 from $11 at Roth Capital
PremiumThe Fly
CervoMed price target lowered to $9 from $11 at Roth Capital
1M ago
CRVO
CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsCRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
CRVO
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
Premium
Ratings
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
2M ago
CRVO
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
Premium
Company Announcements
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
2M ago
8K
CRVO
CervoMed presents neflamapimod MRI data
PremiumThe Fly
CervoMed presents neflamapimod MRI data
2M ago
CRVO
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
PremiumCompany Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
2M ago
8K
CRVO
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
PremiumCompany Announcements
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
3M ago
8K
CRVO
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
PremiumCompany Announcements
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
3M ago
8K
CRVO
CervoMed’s neflamapimod shows efficacy in dementia with DLB
PremiumThe FlyCervoMed’s neflamapimod shows efficacy in dementia with DLB
3M ago
CRVO
CervoMed price target lowered to $11 from $19 at Roth Capital
Premium
The Fly
CervoMed price target lowered to $11 from $19 at Roth Capital
3M ago
CRVO
CervoMed price target raised to $21 from $15 at Chardan
Premium
The Fly
CervoMed price target raised to $21 from $15 at Chardan
3M ago
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >